Abstract
If you belong to a biomedical research pressure group, the most sought-after seat in town may be on a new National Institutes of Health (NIH) advisory council, to be known as the Director9s Council of Public Representatives. The panel, whose outlines began to take shape last week, is meant to ease tensions between NIH and dissatisfied patient-advocacy groups. But it doesn9t look as though seats are being reserved for the most disgruntled of the specific-disease lobbies.